An Italian Experience on Grade 3b Follicular Lymphoma
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.

Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.
Grade 3b Follicular Lymphoma
Overall Response Rate, Number of patients who achieve Complete Response or Partial Response after treatment, End of front-line treatment (evaluated from diagnosis up to 30 months)
Progression Free Survival, Time from last response to nearest relapse or follow-up, From first response to last follow-up for at least 2 years (up to 15 years)|Overall Survival, Time to last follow-up or death, Date of last follow-up for at least 2 years (up to 15 years)
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.

Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.